{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:14:21Z","timestamp":1792088061258,"version":"4.4.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T00:00:00Z","timestamp":1584057600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008123","name":"Centre Scientifique de Monaco","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008123","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Allogeneic hematopoietic stem cell transplantation (HSCT) is, to date, the only curative treatment for sickle cell disease (SCD). Because an human leukocyte antigen (HLA)-matched sibling donor is not always available, alternative stem cell sources such as unrelated or haploidentical related donors have been explored. To date, few series of SCD patients transplanted with an unrelated donor, cord blood, and haploidentical related donor have been reported, but the high rates of rejection and chronic graft versus host disease have limited their widespread application. We describe the outcomes of a retrospective, registry-based, survey on 144 alternative donor HSCT performed for SCD in 30 European Society for Blood and Marrow Transplantation centers between 1999 and 2017. Data on 70 unrelated adult donors (49%), six cord blood (4%), and 68 haploidentical donors (47%; including post-HSCT Cy,\n                      <jats:italic toggle=\"yes\">ex vivo<\/jats:italic>\n                      T-cell depleted, and other haplo-HSCTs) were reported and missing information was updated by the centers. Overall, 16% patients experienced graft failure, Grade II\u2013IV acute GVHD at 100 days was 24%, whereas Grade III\u2013IV was 10%. Chronic GVHD was observed in 24% (limited for 13 patients and extensive for 18 patients). Overall, the 3-year overall survival (OS) was 86% \u00b1 3% and 3-year event-free survival (EFS; considering death and graft failure as events) was 72% \u00b1 4%. We therefore conclude that alternative donor HSCT for SCD can be feasible but efforts in decreasing relapse and GVHD should be promoted to increase its safe and successful utilization. Moreover, a better knowledge of HLA matching and the tailoring of conditioning could help improve EFS and OS.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.hemonc.2019.12.011","type":"journal-article","created":{"date-parts":[[2020,3,16]],"date-time":"2020-03-16T14:10:44Z","timestamp":1584367844000},"page":"181-188","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":34,"title":["Alternative donor hematopoietic stem cell transplantation for sickle cell disease in Europe"],"prefix":"10.4103","volume":"13","author":[{"given":"Eliane","family":"Gluckman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Cappelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graziana Maria","family":"Scigliuolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josu De la","family":"Fuente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selim","family":"Corbacioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-1-20241211","first-page":"1918","article-title":"Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Multicenter investigation of bone marrow transplantation for sickle cell disease","volume":"95","author":"Walters","year":"2000","journal-title":"Blood"},{"key":"R2-1-20241211","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1182\/blood-2007-03-079665","article-title":"Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease","volume":"110","author":"Bernaudin","year":"2007","journal-title":"Blood"},{"key":"R3-1-20241211","first-page":"1548","article-title":"Eurocord, the Pediatric Working Party of the European Society for Blood and Marrow Transplantation, and the Center for International Blood and Marrow Transplant Research","volume":"129","author":"Gluckman","year":"2017","journal-title":"Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation. Blood"},{"key":"R4-1-20241211","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMsa1311707","article-title":"HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry","volume":"371","author":"Gragert","year":"2014","journal-title":"N Engl J Med"},{"key":"R5-1-20241211","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.bbmt.2017.03.001","article-title":"Prospective evaluation of unrelated donor cord blood and haploidentical donor access reveals graft availability varies by patient ancestry: practical implications for donor selection","volume":"23","author":"Kosuri","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"R6-1-20241211","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1182\/blood-2019-124592","article-title":"Human leukocyte antigen matched unrelated donors for patients with sickle cell disease according to geographic origin: results of international donor searches","volume":"134","author":"Tozatto-Maio","year":"2019","journal-title":"Blood"},{"key":"R7-1-20241211","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1182\/blood-2016-05-715870","article-title":"A trial of unrelated donor marrow transplantation for children with severe sickle cell disease","volume":"128","author":"Shenoy","year":"2016","journal-title":"Blood"},{"key":"R8-1-20241211","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/bjh.13352","article-title":"Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in children with sickle cell disease","volume":"169","author":"Strocchio","year":"2015","journal-title":"Br J Haematol"},{"key":"R9-1-20241211","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.bbmt.2017.10.030","article-title":"Outcomes of unrelated donor stem cell transplantation with post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in patients with severe sickle cell disease","volume":"24","author":"Rangarajan","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"R10-1-20241211","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.bbmt.2012.01.019","article-title":"Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN)","volume":"18","author":"Kamani","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"R11-1-20241211","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.bbmt.2013.12.564","article-title":"Unrelated donor allogeneic hematopoietic stem cell transplantation for patients with hemoglobinopathies using a reduced-intensity conditioning regimen and third-party mesenchymal stromal cells","volume":"20","author":"Kharbanda","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"R12-1-20241211","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/j.bbmt.2017.05.027","article-title":"Unrelated umbilical cord blood transplantation for sickle cell disease following reduced-intensity conditioning: results of a phase I trial","volume":"23","author":"Abraham","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"R13-1-20241211","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1182\/blood-2013-10-531764","article-title":"\u201cDesigned\u201d grafts for HLA-haploidentical stem cell transplantation","volume":"123","author":"Martelli","year":"2014","journal-title":"Blood"},{"key":"R14-1-20241211","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.bbmt.2011.01.012","article-title":"Umbilical cord blood transplantation for children with thalassemia and sickle cell disease","volume":"17","author":"Ruggeri","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"R15-1-20241211","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, post transplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"R16-1-20241211","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1182\/blood-2014-03-563817","article-title":"HLA-haploidentical stem cell transplantation after removal of \u03b1\u03b2+ T and B cells in children with nonmalignant disorders","volume":"124","author":"Bertaina","year":"2014","journal-title":"Blood"},{"key":"R17-1-20241211","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41409-019-0550-0","article-title":"Haploidentical CD3 or \u03b1\/\u03b2 T-cell depleted HSCT in advanced stage sickle cell disease","volume":"54","author":"Foell","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"R18-1-20241211","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.bbmt.2018.11.027","article-title":"Haploidentical bone marrow transplantation with post-transplantation cyclophosphamide plus thiotepa improves donor engraftment in patients with sickle cell anemia: results of an International Learning Collaborative","volume":"25","author":"de","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"R19-1-20241211","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1056\/NEJM198409203111207","article-title":"Bone-marrow transplantation in a patient with sickle-cell anemia","volume":"311","author":"Johnson","year":"1984","journal-title":"N Engl J Med"},{"key":"R20-1-20241211","doi-asserted-by":"crossref","first-page":"e543","DOI":"10.3324\/haematol.2019.216788","article-title":"Risk factors and outcomes according to age at transplantation with an HLA-identical sibling for sickle cell disease","volume":"104","author":"Cappelli","year":"2019","journal-title":"Haematologica"},{"key":"R21-1-20241211","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41573-018-0003-2","article-title":"Therapeutic strategies for sickle cell disease: towards a multi-agent approach","volume":"18","author":"Telen","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"R22-1-20241211","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1056\/NEJMoa1609677","article-title":"Gene therapy in a patient with sickle cell disease","volume":"376","author":"Ribeil","year":"2017","journal-title":"N Engl J Med"},{"key":"R23-1-20241211","doi-asserted-by":"crossref","first-page":"4583","DOI":"10.1182\/blood-2019-121952","article-title":"Results of unrelated donor hematopoietic stem cell transplantation for sickle cell disease in Europe on Behalf of Paediatric Diseases (PDWP) and Inborn Errors Working Parties (IEWP) of the EBMT","volume":"134","author":"Gluckman","year":"2019","journal-title":"Blood"},{"key":"R24-1-20241211","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/bmt.2017.49","article-title":"Haploidentical stem cell transplantation with CD3(+)-\/CD19 (+)-depleted peripheral stem cells for patients with advanced stage sickle cell disease and no alternative donor: results of a pilot study","volume":"52","author":"Foell","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"R25-1-20241211","doi-asserted-by":"crossref","first-page":"e585","DOI":"10.1016\/S2352-3026(19)30154-1","article-title":"Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study","volume":"6","author":"Eapen","year":"2019","journal-title":"Lancet Haematol"},{"key":"R26-1-20241211","doi-asserted-by":"crossref","first-page":"e573","DOI":"10.1016\/S2352-3026(19)30158-9","article-title":"Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis","volume":"6","author":"Shouval","year":"2019","journal-title":"Lancet Haematol"}],"container-title":["Hematology\/Oncology and Stem Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387620300340?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387620300340?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/10.1016\/j.hemonc.2019.12.011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:50:20Z","timestamp":1787838620000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1016\/j.hemonc.2019.12.011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1016\/j.hemonc.2019.12.011","relation":{},"ISSN":["1658-3876"],"issn-type":[{"value":"1658-3876","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]}}}